| Traceless Materials–SEVERAL: investment, 202309 financing round Series A €36.6m led by UB FIGG plus other new + all existing investors |
2023-09-25 |
| CARTemis Therapeutics–Germany (govt): grant, 202309c– BMBF grant €1.3m for clinical trials with CAR T-cell therapy targeting BCMA |
2023-09-21 |
| Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront |
2023-09-20 |
| Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties |
2023-09-20 |
| SHS Capital–SEVERAL: investment, 202309 final closing of SHS VI fund adding ca €50 after first close bringing total fund size to €270m |
2023-09-13 |
| Moderna–Immatics: cancer drugs, 202309– strategic r+d collab $120m upfront + >$1.7b funding + milestones + royalties combing tech platforms |
2023-09-11 |
| Oncgnostics–SEVERAL: investment, 202309 financing round €7-digit led by Grande Bio-tech Co Ltd + incl bm-t + HTGF |
2023-09-05 |
| Paptic–SEVERAL: investment, 202309 financing round Series A €23m led by ECBF + incl Ecolab + Itochu Fibre |
2023-09-04 |
| Takara Shuzo–Eppendorf: lab automation equipment, 202308– collab strategic co-marketing agreem automating Takara Bio chemistries on epMotion platforms |
2023-08-25 |
| PhenomeX–Bruker: investment, 202308–202310 acquisition cash tender offer $108m by Bruker at $1/share |
2023-08-17 |
| Bactolife–SEVERAL: investment, 202308 financing round Series A €30m led by Athos + incl Gates Foundation + Novo Holdings et al |
2023-08-08 |
| IO Biotech–SEVERAL: investment, 202308 private placement $75m with existing + new investors |
2023-08-07 |
| AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany |
2023-08-02 |
| Bind-X–SEVERAL: investment, 202308 financing round Series B €10m with HG Ventures + K&K1 + Greeneering Invest + Saxovent |
2023-08-01 |
| BioNTech–Duality Biologics: antibody-drug conjugates, 202308– license excl ww excl China? to develop + manufacture + commercialise DB-1305 |
2023-08-01 |
| Cellbox Solutions–EU (govt): grant, 202308–202507 EIC Accelerator grant €2.5m |
2023-08-01 |
| Reata–Biogen: investment, 202307– acquisition $7.3b in cash by Biogen at $172.5/share ANNOUNCED |
2023-07-28 |
| AaviGen–Hopp Group: investment, 202307 financing round Series B €17m from existing investor DH-LT Investments GmbH |
2023-07-26 |
| Crescendo Biologics–SEVERAL: investment, 202307 financing round $32m with new investor Kreos Capital + all major existing investors |
2023-07-24 |
| CrystalsFirst–NexMR: fragment-based drug discovery, 202307– collab combining crystallography technology with NRM for drug discovery |
2023-07-24 |
| Epigenomics–New Day Diagnostics: investment, 202307– acquisition of substantially all assets up to $12.05m plus license + milestones by New Day SIGNED |
2023-07-24 |
| Immatics–BMS: investment, 202307 private placement $35m with 2.42m ordinary shares at $14.461/share |
2023-07-24 |
| Roche–Alnylam: zilebesiran, 202307– collab $310m upfront + milestones developm + commerc in US w cost/profit sharing + excl ww outside US by Roche |
2023-07-24 |
| TVM–MC Services: public relations, 202307 service existent by MC Services |
2023-07-20 |
| BioNTech–Biotheus: antibody cancer drug, 202307– strategic research collab + ww excl option + license agreement |
2023-07-19 |
| BioNTech–Biotheus: antibody cancer drug, 202311– collab + license ww excl ex-Greater China for PM8002 $55m upfront + >$1b milestones + royalties |
2023-07-19 |
| AATec Medical–SEVERAL: investment, 202307 seed financing round €2.7m from private investors + industry experts + family offices |
2023-07-17 |
| DTx Pharma–Novartis: investment, 202307 acquisition of DTx Pharma for $500m upfront + $500m milestones |
2023-07-17 |
| Tenpoint Therapeutics–SEVERAL: investment, 202307 financing round Series A $70m led by F-Prime Capital + Sofinnova Partners + British Patient Capital |
2023-07-12 |
| Vertama–SEVERAL: investment, 202307 seed financing round 7-digit € led by HTGF |
2023-07-12 |
| Aphea.Bio–SEVERAL: investment, 202307 financing round Series C €70m led by Innovation Industries |
2023-07-11 |
| Celares–Biosynth: investment, 202307 acquisition of Celares by Biosynth |
2023-07-11 |
| Mallia Therapeutics–SEVERAL: investment, 202307c– seed financing round raising ongoing 7/23 |
2023-07-11 |
| BioNTech–Doer Biologics: biopharmaceuticals, 202308– license ww to use Doer Bio discovery to develop + market biotherapeutics against one target |
2023-07-10 |
| Acousia Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| inContAlert–SEVERAL: investment, 202307 pre-seed financing round €1.5m led by HTGF + Bayern Kapital + Carma Fund |
2023-07-01 |
| United Kingdom (govt)–BioNTech: mRNA drugs + vaccines, 202307– strategic collab personalised cancer therapies + anti-infective vaccines + UK RnD Hub |
2023-07-01 |
| Emergence Therapeutics–Lilly: investment, 202306 acquisition 100% of Emergence Therapeutics AG by Eli Lilly |
2023-06-29 |
| Gleamer–SEVERAL: investment, 202306 financing round Series B €27m led by Supernova Invest + co-led by Heal Capital |
2023-06-28 |
| MoonLake–Consilium: public relations, 202306 service existent by Consilium Strategic Communications |
2023-06-28 |
| Astraveus–SEVERAL: investment, 202306 seed financing round €16.5m led by AdBio Partners |
2023-06-27 |
| Docflix–SEVERAL: investment, 202306 seed financing round €2m led by HTGF + Brandenburg Kapital |
2023-06-27 |
| EBAMed–SEVERAL: investment, 202306 financing round Series A €14.35m led by Panakès Partners |
2023-06-27 |
| Hema.to–SEVERAL: investment, 202306 seed financing round €3.6m with Elaia Partners + Heal Capital + HTGF |
2023-06-26 |
| MoonLake–SEVERAL: investment, 202306 public offering $400m+$60m with 8m+1.2m Class A ordinary shares at $50/share |
2023-06-26 |
| Lunaphore–Bio-Techne: investment, 202306– acquisition by of Lunaphore by Bio-Techne ANNOUNCED |
2023-06-22 |
| Tagworks Pharmaceuticals–SEVERAL: investment, 202306 financing round Series A $65m led by Ysios Capital + Gilde Healthcare |
2023-06-22 |
| Pieris–Kendall Investor Relations: public relations, 202306 supply service existent IR by Kendall IR |
2023-06-21 |
| Innovative Health Initiative–EU (govt): grant, 202306– funding €24m for IMAGIO project from IHI |
2023-06-20 |
| Thermosome–Innovative Health Initiative: grant, 202306– funding €1.3m as partner in IMAGIO project of IHI |
2023-06-20 |
| CRISPR Therapeutics–Goldman Sachs: investor conference, 202306 supply service CRISPR Tx participates in GS Annual Global Healthcare Conference 2023 |
2023-06-14 |
| DNTox–SEVERAL: investment, 202306 seed financing round €1.4m led by HTGF |
2023-06-14 |
| Dynamic42–SEVERAL: investment, 202306 financing round Series A mid-7-figure € incl investors bm-t + a familly office |
2023-06-13 |
| Chinook Therapeutics–Novartis: investment, 202306– acquisition $3.2b cash upfront + $300m cash milestones of Chinook by Novartis ANNOUNCED |
2023-06-12 |
| Bruker–Leucadia: investor conference, 202306 supply service Brukers presents at Jefferies 2023 Healthcare Conference |
2023-06-09 |
| Upstream Bio–SEVERAL: investment, 202306 financing round Series B $200m co-led by Enavate Sciences + Venrock Healthcare Capital Partners |
2023-06-08 |
| OntoChem–Holtzbrinck: investment, 202306 acquisition 100% of OntoChem by Digital Science |
2023-06-07 |
| Bayer–Acuitas Therapeutics: LNP technology, 202306– collab €na using LNP technology to deliver RNA payloads to liver |
2023-06-05 |
| ITM–SEVERAL: investment, 202306 financing round €255m led by Temasek |
2023-06-05 |
| 4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms |
2023-06-01 |
| Swiss Life–Bico: real estate, 202306 acquisition €21m of new Scienion property in Berlin by BEOS Light Industrial Germany I fund |
2023-06-01 |
| Synaffix–Lonza: investment, 202306 acquisition €100m upfront cash + €60m milestones of Synaffix by Lonza |
2023-06-01 |
| Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones |
2023-06-01 |
| CARTemis Therapeutics–Germany (govt): grant, 202305– BMBF grant €4.6m to develop CAR T-cell therapy targeting CXCR5 (to MDC+Charité) |
2023-05-26 |
| Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group |
2023-05-25 |
| Prosion–10xDNA: investment, 202205 existent 7-figure seed investment by 10xDNA |
2023-05-23 |
| Oncimmune–Freenome: investment, 202305 acquisition of Oncimmune Ltd by Freenome |
2023-05-22 |
| VectivBio–Ironwood: investment, 202305–202306 acquisition $1b net of cash/debt cash tender offer at $17/share |
2023-05-21 |
| Traceless Materials–Germany (govt): grant, 202305– BMUV funding €5.1m for construction of demonstration plant |
2023-05-19 |
| Exazyme–SEVERAL: investment, 202305 seed financing round €2m from AIX Ventures + Atlantic Labs |
2023-05-15 |
| Nia Health–SEVERAL: investment, 202305 seed financing round €3.5m led by HTGF |
2023-05-15 |
| Repare Therapeutics–Vivlion: gene editing, 202305– supply of PRICSR CRISPR gRNA libraries for synthetic lethal screening by Vivlion |
2023-05-11 |
| UCB–Ariceum Therapeutics: targeted radiopharmaceuticals, 202305– collab strategic r+d for TRTs for solid tumours + immune-related diseasees |
2023-05-11 |
| DiogenX–SEVERAL: investment, 202305 financing round Series A €27.5m led by BIVF + Roche Venture Fund |
2023-05-10 |
| Cambridge Research Biochemicals–Biosynth: investment, 202305 acquisition of CRB by Biosynth |
2023-05-09 |
| PolyPeptide–Numaferm: peptide synthesis, 202305– collab €na Preferred Partner Collaboration Agreement for peptide development + production |
2023-05-09 |
| Roche–Zion Pharma: tyrosine kinase inhibitor, 202305– acqisition ww rights $70m ufpront + near-term MS + $610m milestones + royalties to ZN-A-1041 |
2023-05-09 |
| Midwest Biosolutions–Bionter: analytical instruments, 202305– collab Midwest Bio to promote + sell Bionter products + services in the US |
2023-05-08 |
| Zontal–Bruker: investment, 202305 acquisition €na of Zontal by Bruker |
2023-05-08 |
| Bicycle Therapeutics–Helmholtz: Bicycle radio conjugates, 202305– collab to discovery + develop BRCs for a range of oncology targets with DKFZ |
2023-05-04 |
| Anavo Therapeutics–SEVERAL: investment, 202305 seed financing round extenstion €8.5m with new investor MRL Ventures + all existing investors |
2023-05-02 |
| Medigene–Helmholtz: cancer immunotherapy, 202305– license ww excl to CD40L-CD28 costimulatory swith receptor from Helmholtz Munich |
2023-05-02 |
| Ten23 Health–Bionter: particle counting, 202305– collab developm of methods incl installation of EVE particle counter at Ten23 Heatlh |
2023-05-02 |
| Clickmer Systems–APIS Assay Technologies: investment, 202204 acquisition of Clickmer Systems for single-digit €m by APIS Assay Technologies Ltd |
2023-04-25 |
| CRISPR Therapeutics–Needham: investor conference, 202304 supply service CRISPR Therapeutics presents at virtual Annual Needham Healthcare Conference |
2023-04-19 |
| Forbion–SEVERAL: investment, 202304 final close of Forbion Growth Opportunities Fund II with addit €130m bringing total fund size to hard cap €600m |
2023-04-19 |
| Gilde Investment–SEVERAL: investment, 202304 announced new Gilde Healthcare Venture&Growth VI with €600m investor commitments |
2023-04-19 |
| Ariceum Therapeutics–SEVERAL: investment, 202304 financing round Series A extension €22.75m bringing total Series A to €47.75m |
2023-04-18 |
| Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital |
2023-04-18 |
| Complement Therapeutics–SEVERAL: investment, 202304 financing round Series A €72m led by new investor Gimv |
2023-04-17 |
| Syngenta–Ginkgo Bioworks: seed technology, 202304– collab research using protein engineering + uHTS technologies to design + develop new plant traits |
2023-04-17 |
| CellPhenomics–Kyan Therapeutics: drug development technology, 202304– collab combi Optim.AI technology with PD3D technology for drug development |
2023-04-14 |
| Alentis Therapeutics–SEVERAL: investment, 202304 financing round Series C $105m led by Jeito Capital with Novo Holdings + RA Capital |
2023-04-13 |
| InflaRx–SEVERAL: investment, 202304 public offering $40m + $6m with 9.4m + 1.4m ordinary shares at $4.25/share |
2023-04-11 |
| Merck (US)–Proxygen: molecular glue degraders, 202304– strategic multi-year collab + license agreem upfront payment + €2.55b milestones plus royalties |
2023-04-05 |
| AMSilk–SEVERAL: investment, 202304 financing round Series C extension €24m led by AT Newtec bringing total round to €54m |
2023-04-04 |
| Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202304– supply of nca actinum-225 to Point Biopharma |
2023-04-04 |
| BioNTech–Duality Biologics: antibody-drug conjugates, 202304– license excl ww excl China for DB-1303 + DB-131 $170m upfront + >$1.5b milestones + roy |
2023-04-03 |
| InSphero–SEVERAL: investment, 202303 financing round 8-digit led by Zeiss Ventures |
2023-03-31 |
| Polyplus-transfection–Sartorius: investment, 202303– acquisition €2.4b of Polyplus by SSB from Archimed + Warburg Pincus et al |
2023-03-31 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
